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Introduction
The use of Isoniazid preventive therapy (IPT) which results into lower risk of progression to TB disease and TB related mortality for people living with Human Immunodeficiency Virus (HIV) has been found to be effective in treating latent tuberculosis (TB) infection (LTBI). [1] [2] [3] [4] [5] [6] Effectiveness of IPT with or without ART has been confirmed by many observational studies in low and middle-income settings. [5] [6] [7] [8] In fact, concomitant use helps to reduce the occurrence of TB disease soon after ART initiation which is when the risk is higher. [2, 9] IPT initiation in Ethiopia for people living with HIV during 2013 was at 4.8% which is low. [10] This indicates the inadequacy of implementation of this life saving intervention despite the proven effectiveness. There are several barriers that impede IPT implementation. Medication related barriers which are likely to account for a small fraction of reasons why medication is discontinued or deferred include potential pill burden, side effects, and overlapping side effects with ART medications. [11] The most important factor, however, is the attitude of health care workers towards IPT provision related to concerns with uncertainty in ruling out TB disease, and providers' fear of patients developing TB disease while taking IPT which they believe lead to drug resistance. [12] [13] [14] The evidence, however, indicates that most of these worries are not justified. For instance, one of the feared toxicities is hepatotoxicity and the incidence of clinically significant elevation of liver enzymes is only 6 per 1000 people, which is low. [15] Assessing the risk of Isoniazid drug resistant following IPT use, a meta-analysis of 36,000 patients who took IPT indicated that the risk of emergence of Isoniazid resistance was very low and not statistically significant. [16] Furthermore, the WHO (World Health Organisation) symptom based tuberculosis screening algorithm was found to have negative predictive value of >95%, making it an effective tool to rule out TB disease in PLHIV. [11, 17] While these evidences are adequate to reassure clinicians that IPT use is safe, it is important to find out about the risk of developing TB disease during and after taking IPT to identify and address major risk factors associated with it so as to provide evidence based guidance to health care workers and policy makers. In this study, we describe the incidence of TB disease while taking IPT (defined here as breakthrough TB) and after its completion, as well as factors associated with it among PLHIV receiving chronic HIV care. As a secondary outcome we also describe effect of TB disease on retention in care.
Methods

Study design, population, and setting
This is a retrospective, observational, longitudinal study that used existing records of patients in 11 randomly selected hospitals (out of 35) located in three regions of Ethiopia; namely, Addis Ababa, Gambella, and Southern Nations Nationalities and Peoples (SNNP) Region (Fig  1) . Addis Ababa, which is the capital city of Ethiopia, is totally urban while only 15% of the other regions are urban. The regions were selected because of similarity in their data management system and the authors were familiar with it. Two of the regions, Addis Ababa and Gambella, are high HIV burden/prevalence regions with adult HIV prevalence of 3.4% and 4.8% respectively according to the 2016 HIV prevalence estimates. In the SNNP region, only urban areas where all hospitals are located are with high prevalence rate. Adult prevalence in SNNP region was 0.4%. [18] All government hospitals have been providing chronic HIV care (including ART) and IPT for eligible clients based on the national ART and TB/HIV guidelines since 2005. Eligibility for ART was based on the following criteria: all WHO stage IV clients, WHO stage III clients with CD4�350 and WHO stage I or II with CD4� 200. In the absence of CD4 testing, all WHO stages III clients were eligible for ART. The first line ARV regimens used were according to national and international guidelines. [19, 20] HIV infected clients were screened for TB disease during each clinic visit using WHO recommended symptom-based screening, and symptomatic patients were evaluated by diagnostic tests that included clinical evaluation, sputum smear microscopy, as well as chest radiography. Anti-tuberculosis treatment was provided when TB was diagnosed and IPT was given to those without TB disease depending on availability of Isoniazid and absence of contraindications. Therefore, it means IPT is recommended for all PLHIV not diagnosed with TB disease. Tuberculin skin test (TST) was not available and was not required to start IPT as per treatment guidelines. IPT was provided at a dosage of Isoniazid 300 mg/day for adults and 5-10 mg/kg/ day for children for a period of six months. Patients collected their drugs every month until the treatment was completed. Patients on IPT were monitored at every visit for development of active TB disease, adherence to treatment and adverse drug reactions. [21] Health care workers and data clerks for keeping records of clinical care were trained and supervised so as to maintain accurate records. [22] Study period, population and sampling
The sampling frame for selecting the hospitals constituted 35 hospitals from the three regions. STATA statistical software Version 12 was used to randomly select 11 hospitals. Sample size was estimated based on simple proportion formula taking incident TB disease after starting IPT 1.5% based on study in a similar setting. [9] Taking the level of precision to be 0.5%, confidence interval 95%, and estimated loss of 20%, the sample size was 4,099. Therefore, all newly enrolled PLHIV in chronic HIV care who started IPT in these randomly selected hospitals between September 2005 and October 2013 were studied.
Exposure and outcome variables
The exposure variables of interest are: age, gender, baseline WHO stage, baseline CD4 count, ART treatment status at last observation, and duration on ART.
The primary outcome variable was incident TB disease after starting IPT. The occurrence of TB disease while receiving IPT was defined as breakthrough TB. Incident TB disease that occurred after IPT completion was defined as 'TB after IPT completion'. 'Those who took IPT but did not develop TB disease were classified as 'no TB'.
The secondary outcome variable was retention in care, described as final status at the end of the study. Those retained in care (being active on ART treatment at the end of last observation or in April 2014 were considered as having a favourable outcome. Those who died, stopped treatment or were lost to follow-up despite adequate tracing to locate them, were categorized as having an unfavourable treatment outcome.
Data analysis
MS Access 2007 was used to store and clean the data. STATA statistical software Version 12 was used to do descriptive and analytic analysis. (Look at supporting information S1 Table for the final dataset) Proportions were used to describe exposure and outcome variables. To calculate TB disease incidence, person-time at risk of TB disease was accrued from the date of IPT initiation until appearance of incident TB disease, death, transfer to other facility, loss to follow-up (LTFU), or last visit. Any patient who failed to come for care for over a month and could not be located by treatment supporters was classified as LTFU. Since there was no data on IPT completion, intention-to-treat analysis was used assuming IPT treatment was completed. TB incidence was measured by splitting time every six months. Determinants of incident TB disease were analyzed using Cox regression analysis. Interaction terms were used to determine if risk factors of developing TB while taking IPT was different from that of developing TB after completing IPT. Those variables with p value <0.25 were included in the final model. P value <0.05 was used to determine statistically significant associations in the final model. Finally, determinants of retention in care were identified by studying time to unfavourable final status using Cox regression following the same step as described earlier. Person-time was accrued from time of IPT initiation to occurrence of final status. Health facilities' ID was used to control for clustering by including it as stratifying factor in the regression models.
Ethics
Ethics approval for the study was obtained from the National Research Ethics Review Committee (NRERC) of Ethiopia (reference number 3.10/712/04). Consent forms for individual clients were not required since an existing de-identified and de-linked database was used.
Results
Of 35,789 patients enrolled for treatment in the study sites, 4,484 (12.5%) received IPT. Of those that received IPT, the majority, 79.8% (n = 3,578), also received antiretroviral therapy. The median age of the study sample was 30 years (interquartile range 25-37). Children below 15 years of age constituted 10.8% (n = 483). Female gender accounted for 63.6% (n = 2,854). Most patients (60.7%, n = 2,724) were in WHO stage III or IV at enrolment. The median baseline CD4 cell count was 199/mm 3 (interquartile range 124-316). (Table 1 ) Patients were followed for a median of 2.9 years (inter-quartile range: 1.6-3.9 years).
Incident TB disease
Of 4,484 patients, 88 developed TB (2%). Of these, 24/88 (27.3%) patients were diagnosed with TB while receiving IPT (breakthrough TB). TB incidence was 708 per 100,000 person-years (PY) (95% CI: 575-873). As shown in Fig 2, TB incidence was high in the first 18 months. The incidence of breakthrough TB was 1106 per 100,000 PY (95% CI: 742-1651) while TB incidence after completing IPT was 624 per 100,000 PY (95% CI: 488-797). Seven of 24 (29%) breakthrough TB cases were diagnosed within the first month of IPT initiation. Evaluating the timing of TB cases in relation to ART initiation, 60% (9/15) of breakthrough TB cases occurred in the first six months of ART initiation as compared to 23.7% (14/59) of all TB cases that occurred in the same time period.
Determinants of incident TB disease among patients that took IPT
Retention in care
Overall 82% of patients were on ART treatment at last observation. (Table 4 ) Most patients with unfavourable follow-up outcome were lost to follow-up. Those who didn't develop TB were less likely to have unfavorable final status (adjusted Hazard ratio (95% confidence interval) 0.52 (0.27-1.00)) but it was not statistically significant at the 5% level. Only being male was associated with increased hazard of having unfavourable final status (adjusted Hazard ratio (95% confidence interval) 1.47 (1.19-1.82)). (Table 5 )
Discussion
Breakthrough TB was uncommon among those receiving IPT in the study setting. Its incidence was 1106 per 100,000 person-years on IPT. Slightly more than a quarter of these cases were diagnosed in the first month of starting IPT. This may represent undiagnosed cases that were missed due to failure to properly adhere to WHO's TB screening algorithm or difficulty ruling out TB using AFB and/or Chest X-ray only. The diagnostic challenge may be partially alleviated as there is an increased access to the GeneXpert test across the country, but especially in hospitals where GeneXpert tests are commonly located. [23] Even though breakthrough TB was not specifically described in previous studies, many studies that determined effectiveness of IPT in preventing TB disease among PLHIV invariably illustrated the occurrence of TB after using IPT. Finding from a study in Ethiopia reported a lower incidence of 697 per 100,000 PY. [9] Another study came up with results much lower than the current study with an incidence of 265 per 100,000 PY. [24] A higher incidence (2,100 per 100,000 PY) of TB after IPT use was reported in studies done in three developed nations (USA, Canada, and Spain) and Brazil. In these studies TB burden was higher because most patients did not receive ART [2, 25] while in the current study the reverse was the case.
TB incidence in patients that took IPT is higher (three fold higher) than that of the general population in Ethiopia which approximated at 224 per 100,000 people during 2013. [26, 27] This indicates that even among PLHIV that received IPT and ART, active TB case finding by screening these at risk clients during every clinic visit is critical to detect and treat TB early. In this study those with higher baseline CD4 or on ART were less likely to develop breakthrough TB and TB after IPT completion. This is good news in a time when test-and-treat is being implemented and clients are started on ART at higher CD4 cell counts. [28, 29] This study, however, also supports that the first few months after ART initiation are critical and every patient should be monitored strictly so that immune-reconstitution inflammatory syndrome (IRIS), which is another likely reason behind high occurrence of TB disease soon after ART initiation, can be detected and managed. [28] In this study, the first year was when the highest fraction of cases were detected which coincided with the period that TB IRIS was the highest. This was true for both breakthrough TB and TB diagnosed after IPT completion.
One study [30] described how WHO's TB diagnostic algorithm is not routinely followed in very large numbers of PLHIV screened for TB in South Africa. This happened especially in TB suspects following a negative first test by AFB or GeneXpert. Further test or follow-up was performed in only 24% of individuals. This may be one reason why there were many cases of breakthrough TB cases diagnosed in the first month after IPT initiation. Further assessment is needed to understand what happened in these cases or how adherence to diagnostic algorithm in ART clinics can be improved in the future. IPT uptake in our study setting was low at 12.5% at the end of follow-up. Of course, this includes all cases who received IPT before or after receiving ART and thus does not say anything about the timeliness of IPT provided. For PLHIV, the most important time to receive IPT is before, during, or soon after starting ART where the risk of developing TB is higher. [9] IPT uptake in the study setting is low considering the facilities are hospitals which have better access to IPT. The WHO global TB report during 2013 indicated IPT coverage of 4.8% [10] among eligible PLHIV newly enrolled in HIV care as compared to 52% in 2016 which shows significant improvement. [31] As for the impact on retention in care, after controlling for age, gender, baseline WHO stage and CD4 count, there was no significant difference on the effect of breakthrough TB on remaining in care as compared to those having TB after IPT completion. The negative effect of TB on adherence and even mortality among PLHIV is a well-established fact and was identified in this study as well. [32] This is a multisite study which was adequately powered and one of a few studies to describe breakthrough TB disease among PLHIV receiving IPT. There are some important limitations of this study. First, analysis was on an intention-to-treat basis since data on IPT adherence was not captured at all and IPT completion was not documented. Adherence for IPT in Ethiopia was reported to be 64% and 86% by two studies. Overall, those on ART were found to have better adherence. [33, 34] In this study, most patients also received ART and thus IPT adherence may have been better. The other limitation is that this study utilized secondary data and thus limitations that arise from use of existing records apply here. Also, the findings of the study cannot be generalized to other regions in the country and hence further study with better representation of treatment sites can help to consolidate these findings.
Conclusion
Breakthrough TB was uncommon in the study setting. A significant proportion of it occurred in the first month of treatment and could be due to difficulty in diagnosing TB disease with AFB+/-Chest X-ray or failure to strictly follow TB screening and diagnostic algorithm to rule out TB after adequate follow-up. 
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